Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis

Authors


  • Funding sources: None.

  • Conflicts of interest: A.C.F., L.W., D.G., R.B.W. and C.E.M.G. work in the U.K. National Health Service (NHS). C.E.M.G. has acted as a consultant and/or speaker for Abbott, Centocor, Incyte, Janssen, Leo Pharma, Novartis, Pfizer and Schering-Plough (now MSD), all of which manufacture therapies used in the treatment of psoriasis. R.B.W. has acted as a consultant and/or speaker for Abbott, Janssen, Leo Pharma, Pfizer, Novartis and Schering-Plough (now MSD), all of which manufacture therapies used in the treatment of psoriasis. A.C.F. has received educational support to attend conferences and/or acted as a consultant for Pfizer, Abbott, Janssen, Novartis and Leo Pharma, all of which manufacture therapies used in the treatment of psoriasis.

Ancillary